Biography

Steven Kliewer earned his BS in biochemistry from Brown University in 1985 and his PhD in molecular biology from UCLA in 1990. From 1990-1993, he was a postdoctoral fellow in the laboratory of Dr. Ronald Evans at the Salk Institute, where he began his studies on orphan nuclear receptors. During this period, he discovered the central role that the retinoid receptor RXR plays as an obligate heterodimer partner for the vitamin D receptor, thyroid hormone receptor, retinoic acid receptor, and PPARs.

In 1993, he joined Glaxo, Inc., where he co-founded a scientific group devoted to exploiting orphan nuclear receptors as drug discovery targets. Among his achievements at Glaxo was the discovery that the fatty acid receptor PPAR-gamma is the molecular target for the antidiabetic TZD class of drugs, including rosiglitazone and pioglitazone. He also discovered the xenobiotic receptor PXR and showed that it is responsible for an important class of drug-drug interactions. A practical consequence of this work is that new drugs can be screened efficiently for harmful interactions with other medications.

In 2002, he joined the faculty at UT Southwestern, where he is currently Professor of Molecular Biology and Pharmacology and holds the Nancy B. and Jake L. Hamon Distinguished Chair in Basic Cancer Research. He runs a joint laboratory with Dr. David Mangelsdorf that focuses on the roles of nuclear receptors and endocrine FGFs in regulating diverse aspects of physiology and pathophysiology, including metabolism and metabolic disease.

 

Education

Undergraduate Brown University (1985)
Graduate School University of California-Los Angeles (1990)

Research Interest

  • Endocrine FGFs
  • Metabolism and metabolic disease
  • Nuclear receptors

Publications

Featured Publications LegendFeatured Publications

The Nuclear Receptor DAF-12 Regulates Nutrient Metabolism and Reproductive Growth in Nematodes.
Wang Z, Stoltzfus J, You YJ, Ranjit N, Tang H, Xie Y, Lok JB, Mangelsdorf DJ, Kliewer SA PLoS Genet. 2015 Mar 11 3 e1005027
FGF21 Acts Centrally to Induce Sympathetic Nerve Activity, Energy Expenditure, and Weight Loss.
Owen BM, Ding X, Morgan DA, Coate KC, Bookout AL, Rahmouni K, Kliewer SA, Mangelsdorf DJ Cell Metab. 2014 Aug
FGF21 regulates metabolism and circadian behavior by acting on the nervous system.
Bookout AL, de Groot MH, Owen BM, Lee S, Gautron L, Lawrence HL, Ding X, Elmquist JK, Takahashi JS, Mangelsdorf DJ, Kliewer SA Nat. Med. 2013 Aug
FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis.
Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA, Mangelsdorf DJ Science 2011 Mar 331 6024 1621-4

Honors & Awards

  • National Academy of Sciences
    (2015)
  • Falk Foundation Adolf Windaus Prize
    (2014)
  • Endocrine Society Ernst Oppenheimer Award
    (2005)
  • Aventis Innovative Investigator Award
    (2004)
  • ISSX North American New Investigator Award
    (2003)
  • ASPET John J. Abel Award in Pharmacology
    (2002)

Professional Associations/Affiliations

  • American Society for Pharmacology and Experimental Therapeutics
  • The Endocrine Society